{"title":"\u30a4\u30bd\u30ed\u30a4\u30b7\u30eb\u2212\u30d7\u30ed\u30ea\u30eb\u2212\u30d7\u30ed\u30ea\u30f3\uff08IPP\uff09\u3068\u30d0\u30ea\u30eb\u2212\u30d7\u30ed\u30ea\u30eb\u2212\u30d7\u30ed\u30ea\u30f3\uff08VPP\uff09\u3068\u6b63\u5e38\u8840\u5727\u7dad\u6301\u306b\u95a2\u9023\u3059\u308b\u5065\u5eb7\u5f37\u8abf\u8868\u793a\u306e\u7acb\u8a3c\u306b\u3064\u3044\u3066\u306e\u79d1\u5b66\u7684\u610f\u898b","author_name":"uneyama","width":"100%","published":"2011-10-03 00:00:09","version":"1.0","blog_url":"https://uneyama.hatenadiary.jp/","type":"rich","author_url":"https://blog.hatena.ne.jp/uneyama/","provider_name":"Hatena Blog","description":"Scientific Opinion on the substantiation of a health claim related to isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) and maintenance of normal blood pressure pursuant to Article 13(5) of Regulation (EC) No 1924/2006 EFSA Journal 2011;9(9):2380 [18 pp.]. 30 September 2011 http://www.ef\u2026","blog_title":"\u98df\u54c1\u5b89\u5168\u60c5\u5831blog\u904e\u53bb\u8a18\u4e8b","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Funeyama.hatenadiary.jp%2Fentry%2F20111003%2Fp10\" title=\"\u30a4\u30bd\u30ed\u30a4\u30b7\u30eb\u2212\u30d7\u30ed\u30ea\u30eb\u2212\u30d7\u30ed\u30ea\u30f3\uff08IPP\uff09\u3068\u30d0\u30ea\u30eb\u2212\u30d7\u30ed\u30ea\u30eb\u2212\u30d7\u30ed\u30ea\u30f3\uff08VPP\uff09\u3068\u6b63\u5e38\u8840\u5727\u7dad\u6301\u306b\u95a2\u9023\u3059\u308b\u5065\u5eb7\u5f37\u8abf\u8868\u793a\u306e\u7acb\u8a3c\u306b\u3064\u3044\u3066\u306e\u79d1\u5b66\u7684\u610f\u898b - \u98df\u54c1\u5b89\u5168\u60c5\u5831blog\u904e\u53bb\u8a18\u4e8b\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","provider_url":"https://hatena.blog","url":"https://uneyama.hatenadiary.jp/entry/20111003/p10","categories":["EFSA"],"image_url":null,"height":"190"}